Integrated Research Facility at Fort Detrick

$39,613,894ZIDFY2018AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Paper 30169850 Paper 30165875 Paper 30107445 Paper 30053050 Paper 30049622 Paper 30032267 Paper 30016444 Paper 30010950 Paper 29982632 Paper 29939303 Paper 29920552 Paper 29742102 Paper 29622497 Paper 29566079 Paper 29566060 Paper 29518913 Paper 29481881 Paper 29462184 Paper 29352230 Paper 29332158 Paper 29301535 Paper 29263876 Paper 29253164 Paper 29143192 Paper 28725019 Paper 28662754 Paper 28643203 Paper 28403145 Paper 28368541 Paper 27974564 Paper 27919178 Paper 27807241 Paper 27768081 Paper 27768063 Paper 27768056 Paper 27768036 Paper 27676345 Paper 27460797 Paper 27456709 Paper 27247341 Paper 27179769 Paper 27166137 Paper 27043611 Paper 26963736 Paper 26908578 Paper 26888429 Paper 26828465 Paper 26573211 Paper 26374912 Paper 26342468 Paper 26218507 Paper 26190637 Paper 26116113 Paper 25972539 Paper 25970823 Paper 25957962 Paper 25864502 Paper 25695153 Paper 25487801 Paper 25421896 Paper 25414499 Paper 25409519 Paper 25355889 Paper 25301647 Paper 25187550 Paper 24841273 Paper 24792843 Paper 24687975 Paper 24585711 Paper 24402304 Paper 24323636 Paper 24109228 Paper 23874198 Paper 23737747 Paper 23577120 Paper 23417351 Paper 23358612 Paper 23209706 Paper 23170178 Paper 23001720 Paper 22932924 Paper 22884034 Paper 22607481 Paper 22182595 Paper 21940414 Patent 10434116

Abstract

In FY18, the Integrated Research Facility in the Division of Clinical Research has continued to provide research facilitation through core capabilities that include imaging, outbreak response in West Africa, clinical pathology, anatomic pathology, electron microscopy, confocal microscopy, immunology, and cell culture. Support was provided primarily to a large number of academic and industrial collaborators as well as to the Emerging Viral Pathogens section in the Division of Intramural Research (DIR) to facilitate discovery of medical countermeasures and improve diagnostics for emerging infectious diseases and biodefense pathogens. This facilitation was concentrated primarily on Ebola, Marburg, Nipah, and Lassa viruses and MERS CoV.

View original record on NIH RePORTER →